Atotech's stock was trading at $25.52 at the beginning of 2022. Since then, ATC stock has decreased by 13.1% and is now trading at $22.17. View the best growth stocks for 2022 here. Are investors shorting Atotech? Atotech saw a increase in short interest in July.
Full Answer
Who sold AGTC stock in the last quarter?
AGTC stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Dimensional Fund Advisors LP, Squarepoint Ops LLC, Colony Group LLC, and Citadel Advisors LLC. View insider buying and selling activity for Applied Genetic Technologies or view top insider-selling stocks.
Is applied Genetic Technologies (AGT) a good stock to buy?
Applied Genetic Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings. According to analysts' consensus price target of $21.00, Applied Genetic Technologies has a forecasted upside of 955.3% from its current price of $1.99.
When is applied genetic technologies expected to release its quarterly earnings?
Applied Genetic Technologies is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022. View our earnings forecast for Applied Genetic Technologies.
Who is new AGTC CEO Jonathan Lieber?
“We are thrilled to welcome Jonathan Lieber to the AGTC team,” said Sue Washer, President and CEO of AGTC. “He’s a seasoned financial and ope
Will AGTC stock recover?
The Wall Street analyst predicted that Applied Genetic Technologies's share price could reach $5.00 by May 18, 2023. The average Applied Genetic Technologies stock price prediction forecasts a potential upside of 1,219.26% from the current AGTC share price of $0.38.
What is AGTC price target?
Applied Genetic Technologies Corp (NASDAQ:AGTC) The 7 analysts offering 12-month price forecasts for Applied Genetic Technologies Corp have a median target of 10.00, with a high estimate of 24.00 and a low estimate of 2.00. The median estimate represents a +2,584.56% increase from the last price of 0.37.
Is Applied Genetic Technologies stock a buy?
Applied Genetic Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Should I invest AGTC?
The financial health and growth prospects of AGTC, demonstrate its potential to underperform the market. It currently has a Growth Score of D. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A.
Whats a good PEG ratio?
What Is a Good PEG Ratio? As a general rule, a PEG ratio of 1.0 or lower suggests a stock is fairly priced or even undervalued. A PEG ratio above 1.0 suggests a stock is overvalued.
What does a high PEG ratio mean?
In theory, a PEG ratio value of 1 represents a perfect correlation between the company's market value and its projected earnings growth. PEG ratios higher than 1.0 are generally considered unfavorable, suggesting a stock is overvalued.
AGTC Announces Robust Improvements in Visual Sensitivity in Adult and Pediatric Patients, and Plans to Continue Clinical Development of AGTC-401 in Patients with CNGB3 Achromatopsia
AGTC-401 demonstrated a favorable safety profile through second-highest dose (1.1E+12 vg/mL) in ACHMB3 pediatric patientsAt the dose of 1.1E+12 vg/mL greater than 50% of the combined adults and children that received AGTC-401 were responders based on improvements in visual sensitivity Totality of data from adult and pediatric patients indicate biologic activity and reaffirm previous positive safety findings in adultsCompany to host conference call to review data today at 8:00 a.m.
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 14, 2022
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb.
About Applied Genetic Technologies
Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology.
Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions
6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 6 buy ratings for the stock.
